Teresa R Johnson

Summary

Affiliation: GenVec Inc
Country: USA

Publications

  1. pmc Respiratory syncytial virus glycoprotein G interacts with DC-SIGN and L-SIGN to activate ERK1 and ERK2
    Teresa R Johnson
    Viral Pathogenesis Laboratorya and Structural Biology Section, b Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    J Virol 86:1339-47. 2012
  2. pmc Pulmonary eosinophilia requires interleukin-5, eotaxin-1, and CD4+ T cells in mice immunized with respiratory syncytial virus G glycoprotein
    Teresa R Johnson
    Vaccine Research Center, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD 20892 3017, USA
    J Leukoc Biol 84:748-59. 2008
  3. pmc Characterization of respiratory syncytial virus M- and M2-specific CD4 T cells in a murine model
    Jie Liu
    Vaccine Research Center, NIAID, National Institutes of Health, 40 Convent Dr, Bethesda, MD 20892 3017, USA
    J Virol 83:4934-41. 2009
  4. pmc Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV
    Teresa R Johnson
    VRC, NIAID, NIH, Bldg 40 Room 2614, 40 Convent Dr, MSC 3017, Bethesda, MD 20892 3017, USA
    J Virol 78:6024-32. 2004
  5. pmc Vbeta14(+) T cells mediate the vaccine-enhanced disease induced by immunization with respiratory syncytial virus (RSV) G glycoprotein but not with formalin-inactivated RSV
    Teresa R Johnson
    Vaccine Research Center, NIAID, NIH, Bldg 40, Room 2614, 40 Convent Dr, MSC 3017, Bethesda, MD 20892 3017, USA
    J Virol 78:8753-60. 2004
  6. pmc Epitope-specific regulatory CD4 T cells reduce virus-induced illness while preserving CD8 T-cell effector function at the site of infection
    Jie Liu
    Vaccine Research Center, NIAID, National Institutes of Health, 40 Convent Dr, Bethesda, MD 20892 3017, USA
    J Virol 84:10501-9. 2010
  7. ncbi request reprint Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection
    Teresa R Johnson
    Viral Pathogenesis Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA
    Pediatr Infect Dis J 23:S46-57. 2004
  8. pmc TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity
    Teresa R Johnson
    Vaccine Research Center, Viral Pathogenesis Laboratory, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892 3017, USA
    Vaccine 27:3045-52. 2009
  9. pmc Treatment with anti-LFA-1 delays the CD8+ cytotoxic-T-lymphocyte response and viral clearance in mice with primary respiratory syncytial virus infection
    John A Rutigliano
    Vaccine Research Center, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 78:3014-23. 2004
  10. pmc Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin-4
    Lewis H McCurdy
    Vaccine Research Center NIAID NIH, 40 Convent Drive, MSC 3017, Building 40, Room 2502, Bethesda, MD 20892 3017, USA
    J Virol 78:12471-9. 2004

Collaborators

Detail Information

Publications15

  1. pmc Respiratory syncytial virus glycoprotein G interacts with DC-SIGN and L-SIGN to activate ERK1 and ERK2
    Teresa R Johnson
    Viral Pathogenesis Laboratorya and Structural Biology Section, b Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    J Virol 86:1339-47. 2012
    ....
  2. pmc Pulmonary eosinophilia requires interleukin-5, eotaxin-1, and CD4+ T cells in mice immunized with respiratory syncytial virus G glycoprotein
    Teresa R Johnson
    Vaccine Research Center, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD 20892 3017, USA
    J Leukoc Biol 84:748-59. 2008
    ..These findings have important implications for the evaluation of candidate RSV vaccines...
  3. pmc Characterization of respiratory syncytial virus M- and M2-specific CD4 T cells in a murine model
    Jie Liu
    Vaccine Research Center, NIAID, National Institutes of Health, 40 Convent Dr, Bethesda, MD 20892 3017, USA
    J Virol 83:4934-41. 2009
    ..Characterization of epitope-specific CD4 T cells by novel fluorochrome-conjugated peptide-I-A(b) tetramers allows detailed analysis of their roles in RSV pathogenesis and immunity...
  4. pmc Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV
    Teresa R Johnson
    VRC, NIAID, NIH, Bldg 40 Room 2614, 40 Convent Dr, MSC 3017, Bethesda, MD 20892 3017, USA
    J Virol 78:6024-32. 2004
    ....
  5. pmc Vbeta14(+) T cells mediate the vaccine-enhanced disease induced by immunization with respiratory syncytial virus (RSV) G glycoprotein but not with formalin-inactivated RSV
    Teresa R Johnson
    Vaccine Research Center, NIAID, NIH, Bldg 40, Room 2614, 40 Convent Dr, MSC 3017, Bethesda, MD 20892 3017, USA
    J Virol 78:8753-60. 2004
    ....
  6. pmc Epitope-specific regulatory CD4 T cells reduce virus-induced illness while preserving CD8 T-cell effector function at the site of infection
    Jie Liu
    Vaccine Research Center, NIAID, National Institutes of Health, 40 Convent Dr, Bethesda, MD 20892 3017, USA
    J Virol 84:10501-9. 2010
    ..Achieving the optimal balance of regulatory and effector T-cell function is an important consideration for designing future vaccines...
  7. ncbi request reprint Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection
    Teresa R Johnson
    Viral Pathogenesis Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA
    Pediatr Infect Dis J 23:S46-57. 2004
    ....
  8. pmc TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity
    Teresa R Johnson
    Vaccine Research Center, Viral Pathogenesis Laboratory, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892 3017, USA
    Vaccine 27:3045-52. 2009
    ..Furthermore, these data underscore that amplification of anti-viral immune responses may result in immunopathology rather than immune-mediated protection...
  9. pmc Treatment with anti-LFA-1 delays the CD8+ cytotoxic-T-lymphocyte response and viral clearance in mice with primary respiratory syncytial virus infection
    John A Rutigliano
    Vaccine Research Center, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 78:3014-23. 2004
    ..These results may prove useful in the development of new therapies to combat RSV infection or other inflammatory diseases...
  10. pmc Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin-4
    Lewis H McCurdy
    Vaccine Research Center NIAID NIH, 40 Convent Drive, MSC 3017, Building 40, Room 2502, Bethesda, MD 20892 3017, USA
    J Virol 78:12471-9. 2004
    ..These data support the continued development of MVA as an alternative candidate vaccine for smallpox...
  11. ncbi request reprint IL-13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challenge
    Teresa R Johnson
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive MSC 3017, Building 40, Bethesda, MD 20892, USA
    J Immunol 170:2037-45. 2003
    ....
  12. pmc Primary human mDC1, mDC2, and pDC dendritic cells are differentially infected and activated by respiratory syncytial virus
    Teresa R Johnson
    Viral Pathogenesis Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health Bethesda, Bethesda, Maryland, United States of America
    PLoS ONE 6:e16458. 2011
    ..Defining the influence of RSV on the function of selected DC subsets may improve the likelihood of achieving protective vaccine-induced immunity...
  13. pmc RhoA signaling is required for respiratory syncytial virus-induced syncytium formation and filamentous virion morphology
    Tara L Gower
    Vaccine Research Center, Building 40, Room 2502, NIAID, NIH, 40 Convent Dr, MSC 3017, Bethesda, MD 20892 3017, USA
    J Virol 79:5326-36. 2005
    ..These data suggest that viral filamentous protuberances characteristic of RSV infection are associated with RhoA signaling, are important for filamentous virion morphology, and may play a role in initiating cell-to-cell fusion...
  14. ncbi request reprint Respiratory syncytial virus and innate immunity: a complex interplay of exploitation and subversion
    Teresa R Johnson
    Vaccine Research Center, NIAID, NIH, Building 40 Room 2614, 40 Convent Drive MSC3017, Bethesda, MD 20892, USA
    Expert Rev Vaccines 5:371-80. 2006
    ..This review will address the impact of these findings on respiratory syncytial virus research...
  15. ncbi request reprint Respiratory syncytial virus immunobiology and pathogenesis
    Barney S Graham
    Viral Pathogenesis Laboratory, National Institutes of Health, Bethesda, Maryland 20892 3017, USA
    Virology 297:1-7. 2002